Cargando…

Rituximab Followed by Belimumab Controls Severe Lupus Nephritis and Bullous Pemphigoid in Systemic Lupus Erythematosus Refractory to Several Combination Therapies

Systemic lupus erythematosus (SLE) and bullous pemphigoid (BP) are chronic autoimmune diseases in which B cells play an important pathogenic role in the different stages of the disease. B cell-targeted therapies have been suggested as a new rational approach for treating SLE. Rituximab (RTX), an ant...

Descripción completa

Detalles Bibliográficos
Autores principales:	Petricca, Luca, Gigante, Maria Rita, Paglionico, Annamaria, Costanzi, Stefano, Vischini, Gisella, Di Mario, Clara, Varriano, Valentina, Tanti, Giacomo, Tolusso, Barbara, Alivernini, Stefano, Grandaliano, Giuseppe, Ferraccioli, Gianfranco, Gremese, Elisa
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2020
Materias:	Medicine
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7657367/ https://www.ncbi.nlm.nih.gov/pubmed/33195302 http://dx.doi.org/10.3389/fmed.2020.553075

Ejemplares similares

Peripheral blood CD4(pos)CD25(pos)FoxP3(pos) cells and inflammatory cytokines as biomarkers of response in rheumatoid arthritis patients treated with CTLA4-Ig
por: Elisa, Gremese, et al.
Publicado: (2022)

Correction: Peripheral blood CD4(pos)CD25(pos)FoxP3(pos) cells and inflammatory cytokines as biomarkers of response in rheumatoid arthritis patients treated with CTLA4-Ig
por: Gremese, Elisa, et al.
Publicado: (2022)

Belimumab for systemic lupus erythematosus – Focus on lupus nephritis
por: Plüß, Marlene, et al.
Publicado: (2022)

Obesity as a Risk and Severity Factor in Rheumatic Diseases (Autoimmune Chronic Inflammatory Diseases)
por: Gremese, Elisa, et al.
Publicado: (2014)

Chemerin and PEDF Are Metaflammation-Related Biomarkers of Disease Activity and Obesity in Rheumatoid Arthritis
por: Tolusso, Barbara, et al.
Publicado: (2018)

Systemic Lupus Erythematosus and Bullous Pemphigoid with Dramatic Response to Dapsone
por: Maggio, Maria Cristina, et al.
Publicado: (2017)

Refractory adult-onset Still disease complicated by macrophage activation syndrome and acute myocarditis: A case report treated with high doses (8 mg/kg/d) of anakinra
por: Parisi, Federico, et al.
Publicado: (2017)

JAK inhibition by methotrexate (and csDMARDs) may explain clinical efficacy as monotherapy and combination therapy
por: Gremese, Elisa, et al.
Publicado: (2019)

Overweight/obesity affects histological features and inflammatory gene signature of synovial membrane of Rheumatoid Arthritis
por: Alivernini, Stefano, et al.
Publicado: (2019)

Differential synovial tissue biomarkers among psoriatic arthritis and rheumatoid factor/anti-citrulline antibody-negative rheumatoid arthritis
por: Alivernini, Stefano, et al.
Publicado: (2019)

The Role of High-Mobility Group Box-1 and Its Crosstalk with Microbiome in Rheumatoid Arthritis
por: Biscetti, Federico, et al.
Publicado: (2017)

The forgotten key players in rheumatoid arthritis: IL-8 and IL-17 – Unmet needs and therapeutic perspectives
por: Gremese, Elisa, et al.
Publicado: (2023)

An update on belimumab for the treatment of lupus
por: Thanou-Stavraki, Aikaterini, et al.
Publicado: (2011)

Belimumab in systemic lupus erythematosus
por: Vilas-Boas, Andreia, et al.
Publicado: (2015)

Belimumab in Systemic Lupus Erythematosus
por: Srivastava, Ankita
Publicado: (2016)

De novo lupus nephritis during treatment with belimumab
por: Parodis, Ioannis, et al.
Publicado: (2020)

Tapering and discontinuation of TNF-α blockers without disease relapse using ultrasonography as a tool to identify patients with rheumatoid arthritis in clinical and histological remission
por: Alivernini, Stefano, et al.
Publicado: (2016)

Synovial Predictors of Differentiation to Definite Arthritis in Patients With Seronegative Undifferentiated Peripheral Inflammatory Arthritis: microRNA Signature, Histological, and Ultrasound Features
por: Alivernini, Stefano, et al.
Publicado: (2018)

Efficacy of novel monoclonal antibody belimumab in the treatment of lupus nephritis
por: Frieri, Marianne, et al.
Publicado: (2015)

Belimumab in Lupus Nephritis: A Systematic Review and Meta-Analysis
por: Shrestha, Sanjeev, et al.
Publicado: (2021)

Urine proteomic insights from the belimumab in lupus nephritis trial
por: Weeding, Emma, et al.
Publicado: (2022)

Diagnosis and clinical severity markers of bullous pemphigoid
por: Schmidt, Enno, et al.
Publicado: (2009)

No higher risk of respiratory symptoms in Italian rheumatological patients under IL-6R-inhibitor therapy in SARS-CoV-2 pandemic
por: Alivernini, Stefano, et al.
Publicado: (2020)

Synovial features of patients with rheumatoid arthritis and psoriatic arthritis in clinical and ultrasound remission differ under anti-TNF therapy: a clue to interpret different chances of relapse after clinical remission?
por: Alivernini, Stefano, et al.
Publicado: (2017)

Systemic Bone Density at Disease Onset Is Associated With Joint Erosion Progression in Early Naive to Treatment Rheumatoid Arthritis: A Prospective 12-Month Follow-Up Open-Label Study
por: Bruno, Dario, et al.
Publicado: (2021)

Serum Albumin Levels: A Biomarker to Be Repurposed in Different Disease Settings in Clinical Practice
por: Gremese, Elisa, et al.
Publicado: (2023)

Paradoxical arthritis occurring during anti-TNF in patients with inflammatory bowel disease: histological and immunological features of a complex synovitis
por: Alivernini, Stefano, et al.
Publicado: (2018)

Treatment Using Both Voclosporin and Belimumab in Four Patients With Lupus Nephritis
por: Baum, Rebecca, et al.
Publicado: (2023)

Pharmacokinetics of Belimumab in Children With Systemic Lupus Erythematosus
por: Dimelow, Richard, et al.
Publicado: (2020)

Efficacy and Safety of Dupilumab in Moderate-to-Severe Bullous Pemphigoid
por: Zhang, Yihua, et al.
Publicado: (2021)

Efficacy and safety of belimumab/low-dose cyclophosphamide therapy in moderate-to-severe systemic lupus erythematosus
por: Cheng, Hao, et al.
Publicado: (2022)

Bullous pemphigoid
por: Miyamoto, Denise, et al.
Publicado: (2019)

MicroRNA-155 influences B-cell function through PU.1 in rheumatoid arthritis
por: Alivernini, Stefano, et al.
Publicado: (2016)

Efficacy of belimumab monotherapy in high infectious risk patient affected by lupus nephritis
por: D’Alessandro, Roberto, et al.
Publicado: (2021)

Collagen Specific T-Cell Repertoire and HLA-DR Alleles: Biomarkers of Active Refractory Rheumatoid Arthritis
por: Di Sante, Gabriele, et al.
Publicado: (2015)

MicroRNA-155—at the Critical Interface of Innate and Adaptive Immunity in Arthritis
por: Alivernini, Stefano, et al.
Publicado: (2018)

Characterization of inflammatory cell infiltrate of scleroderma skin: B cells and skin score progression
por: Bosello, Silvia, et al.
Publicado: (2018)

New treatment options for lupus – a focus on belimumab
por: Chiche, Laurent, et al.
Publicado: (2012)

Management of Pediatric Systemic Lupus Erythematosus: Focus on Belimumab
por: Guzman, Marla, et al.
Publicado: (2020)

Impact of Belimumab on Organ Damage in Systemic Lupus Erythematosus
por: Urowitz, Murray B., et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_bsoickakb01i84pl9vcuido5o1